NantHealth (NYSE: NH) is one of 20 publicly-traded companies in the “Medical Software & Technology Services” industry, but how does it contrast to its competitors? We will compare NantHealth to similar businesses based on the strength of its valuation, earnings, analyst recommendations, institutional ownership, dividends, risk and profitability.
This is a summary of recent ratings and price targets for NantHealth and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
NantHealth currently has a consensus target price of $9.25, indicating a potential upside of 172.06%. As a group, “Medical Software & Technology Services” companies have a potential upside of 21.52%. Given NantHealth’s stronger consensus rating and higher possible upside, analysts clearly believe NantHealth is more favorable than its competitors.
Valuation & Earnings
This table compares NantHealth and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|NantHealth Competitors||$422.43 million||-$16.79 million||391.91|
NantHealth’s competitors have higher revenue, but lower earnings than NantHealth. NantHealth is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This table compares NantHealth and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
64.6% of shares of all “Medical Software & Technology Services” companies are owned by institutional investors. 21.9% of shares of all “Medical Software & Technology Services” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
NantHealth competitors beat NantHealth on 7 of the 10 factors compared.
NantHealth, Inc. is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples. The Company also offers Nant Operating System (NantOS) and NantOS applications to healthcare providers and payors, self-insured employers and biopharmaceutical companies. It offers CLINICS, an integrated solution that includes GPS Cancer, NantOS and the NantOS applications. The CLINICS solution includes System Infrastructure, Knowledge Platform, Provider Platform and Payor Platform.
Receive News & Ratings for NantHealth Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth Inc and related companies with MarketBeat.com's FREE daily email newsletter.